Shire Settles Patent Suit Against Teva Over Generic Intuniv
This article is for subscribers only.
Shire Plc settled a patent lawsuit against Teva Pharmaceutical Industries Ltd., paving the way for lower-cost generic copies of the drug Intuniv, used to treat attention deficit hyperactivity disorder.
Teva, the world’s largest generic-drug company, will get a license to market a version of the drug, Dublin-based Shire said today in a statement. The license takes effect once another generic-drug maker, Actavis Inc., has sold the drug for six months starting in December 2014.